

ESTTA Tracking number: **ESTTA1046912**

Filing date: **04/03/2020**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Proceeding No.	91247175
Filing Party	Plaintiff Atara Biotherapeutics, Inc.
Other Party	Defendant Allogene Therapeutics, Inc.
Pending Motion	There is no motion currently pending and no other motion is being filed concurrent with this consent motion.

Consent Motion for Suspension for Settlement

The parties are actively engaged in negotiations for the settlement of this matter. Atara Biotherapeutics, Inc. requests that this proceeding be suspended for 60 days to allow the parties to continue their settlement efforts.

Proceedings to resume on **06/03/2020**.

Time to Answer	05/04/2019 (CLOSED)
Deadline for Discovery Conference	06/03/2019 (CLOSED)
Discovery Opens	06/03/2019 (CLOSED)
Initial Disclosures Due	11/25/2019 (CLOSED)
Expert Disclosures Due	06/23/2020
Discovery Closes	07/23/2020
Plaintiff's Pretrial Disclosures Due	09/06/2020
Plaintiff's 30-day Trial Period Ends	10/21/2020
Defendant's Pretrial Disclosures Due	11/05/2020
Defendant's 30-day Trial Period Ends	12/20/2020
Plaintiff's Rebuttal Disclosures Due	01/04/2021
Plaintiff's 15-day Rebuttal Period Ends	02/03/2021
Plaintiff's Opening Brief Due	04/04/2021
Defendant's Brief Due	05/04/2021
Plaintiff's Reply Brief Due	05/19/2021
Request for Oral Hearing (optional) Due	05/29/2021

Atara Biotherapeutics, Inc. has secured the express consent of all other parties to this proceeding for the suspension and resetting of dates requested herein.

Certificate of Service

The undersigned hereby certifies that a copy of this filing has been served upon all parties, at their address of record by Email on this date.

Respectfully submitted,

/Jesse A. Salen/

Jesse A. Salen

docteting@sheppardmullin.com, jsalen@sheppardmullin.com, jelee@sheppardmullin.com

04/03/2020